Because of the reported definitive role of EZH2 dysregulation in cancer initiation and progression, previous studies have shed the light on the use of selective EZH2 inhibitors in controlling carcinogenesis along with examining their safety profile to be administered clinically to patients with different malignancies [23]. Here, EZH2 is linked to cancer.